Composites of N-butyl-N-methyl-1-phenylpyrrolo[1,2-a]pyrazine-3-carboxamide with Polymers: Effect of Crystallinity on Solubility and Stability.
amorphous solid dispersions
antidepressants
anxiolytics
bioavailability
composite
solubility
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
30 Jul 2023
30 Jul 2023
Historique:
received:
01
06
2023
revised:
19
07
2023
accepted:
28
07
2023
medline:
14
8
2023
pubmed:
12
8
2023
entrez:
12
8
2023
Statut:
epublish
Résumé
This work aimed to develop and characterize a water-soluble, high-release active pharmaceutical ingredient (API) composite based on the practically water-insoluble API N-butyl-N-methyl-1-phenylpyrrolo[1,2-a]pyrazine-3-carboxamide (GML-3), a substance with antidepressant and anxiolytic action. This allows to ensure the bioavailability of the medicinal product of combined action. Composites obtained by the method of creating amorphous solid dispersions, where polyvinylpyrrolidone (PVP) or Soluplus
Identifiants
pubmed: 37569589
pii: ijms241512215
doi: 10.3390/ijms241512215
pmc: PMC10418436
pii:
doi:
Substances chimiques
Polymers
0
polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer
0
Povidone
FZ989GH94E
Water
059QF0KO0R
Pyrazines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Pharm. 2020 Apr 30;580:119240
pubmed: 32197983
Eur J Pharm Sci. 2021 Feb 1;157:105642
pubmed: 33189903
Eur J Pharm Biopharm. 2018 Mar;124:147-157
pubmed: 29269154
Pharm Res. 2017 Sep;34(9):1754-1772
pubmed: 28523384
Eur J Pharm Biopharm. 2019 Dec;145:98-112
pubmed: 31698042
J Pharm Sci. 2021 Apr;110(4):1470-1479
pubmed: 33333143
Int J Pharm. 2019 May 1;562:113-123
pubmed: 30902705
J Pharm Sci. 2021 Jul;110(7):2703-2717
pubmed: 33609521
Carbohydr Polym. 2014 Apr 15;104:166-74
pubmed: 24607174
J Pharm Sci. 2018 Sep;107(9):2385-2398
pubmed: 29752945
J Pharm Sci. 2022 Nov;111(11):3114-3129
pubmed: 35921915
Mol Pharm. 2016 Apr 4;13(4):1339-46
pubmed: 26954586
Int J Pharm. 2020 Nov 30;590:119925
pubmed: 33011255
Bioorg Med Chem. 2015 Jul 1;23(13):3368-78
pubmed: 25937237
Eur J Pharm Sci. 2022 Feb 1;169:106086
pubmed: 34861411
Eur J Pharm Biopharm. 2021 Jan;158:323-335
pubmed: 33296719
Mol Pharm. 2014 Nov 3;11(11):4228-37
pubmed: 25325389
Int J Pharm. 2020 Oct 15;588:119741
pubmed: 32783978
J Pharm Anal. 2019 Feb;9(1):34-39
pubmed: 30740255
Int J Pharm. 2021 Sep 5;606:120902
pubmed: 34293468
Int J Pharm. 2022 Apr 5;617:121625
pubmed: 35259442
J Pharm Sci. 2021 Apr;110(4):1495-1512
pubmed: 32818440
Saudi Pharm J. 2017 Mar;25(3):419-439
pubmed: 28344498
Life Sci. 2022 Feb 15;291:120301
pubmed: 34999114
Eksp Klin Farmakol. 2016;79(1):7-11
pubmed: 27159950
Int J Pharm. 2020 Nov 15;589:119845
pubmed: 32931845
Int J Pharm. 2023 Feb 5;632:122564
pubmed: 36586638
Eur J Pharm Sci. 2020 Apr 15;146:105276
pubmed: 32092362
J Control Release. 2018 Jan 10;269:110-127
pubmed: 29117503
Int J Pharm. 2023 Apr 5;636:122745
pubmed: 36822340
J Pharm Sci. 2023 Jan;112(1):8-18
pubmed: 35948156
Saudi Pharm J. 2022 Jun;30(6):711-725
pubmed: 35812143
J Pharm Sci. 2022 Sep;111(9):2496-2504
pubmed: 35405124